Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 5
2002 3
2003 4
2004 2
2005 3
2006 6
2007 4
2008 5
2009 10
2010 13
2011 13
2012 15
2013 23
2014 18
2015 7
2016 16
2017 11
2018 15
2019 27
2020 42
2021 55
2022 35
2023 48
2024 40
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 31301099

358 results

Results by year

Filters applied: . Clear all
Page 1
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Naik S, et al. Transpl Infect Dis. 2019 Oct;21(5):e13145. doi: 10.1111/tid.13145. Epub 2019 Jul 31. Transpl Infect Dis. 2019. PMID: 31301099 Free PMC article.
Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV. Patel C, et al. Transplant Cell Ther. 2023 Feb;29(2):132.e1-132.e5. doi: 10.1016/j.jtct.2022.10.023. Epub 2022 Nov 9. Transplant Cell Ther. 2023. PMID: 36334653 Free article.
High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, Walker JT, Fonseca K, Daly A, Duggan P, Stewart D, Russell JA, Storek J. Hoegh-Petersen M, et al. Bone Marrow Transplant. 2011 Aug;46(8):1104-12. doi: 10.1038/bmt.2010.272. Epub 2010 Nov 8. Bone Marrow Transplant. 2011. PMID: 21057556
358 results